All In Biotech

Drug Trial Radar · NCT03990688

A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects

A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Effect of Multiple Oral Doses of AK3280 on Renal Function in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Oct 3, 2019

Primary completion

Sep 9, 2020

Study completion Sep 21, 2020

Sponsor

Sponsor type
Industry
First posted
Jun 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

AK3280 is being developed to further improve the long-term efficacy and tolerability of treatment options for patients with fibrotic disorders.This study will evaluate the effect of AK3280 treatment on renal function and safety, and the PK of AK3280 compared with placebo in healthy subjects.

Conditions

  • Healthy

Interventions

  • AK3280Drug

    Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral

  • PlaceboDrug

    Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Directly measured absolute glomerular filtration rate (mGFR) results.Time frame: Days -1, 7, and 14.
  2. Change from baseline mGFR results.Time frame: Days 7 and 14.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CTC Clinical Trial Consultants AB

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.